ESMO 2017 | Brain metastasis: an important prognostic factor in melanoma
The spread of melanoma to the brain is a serious factor in determining the prognosis of patients suffering from this disease. Paolo Ascierto, MD from the National Tumour Institute Fondazione G. Pascale, Naples, Italy talks to us from the 2017 European Society for Medical Oncology (ESMO) conference in Madrid, Spain to discuss the preliminary data of two ongoing clinical trials. COMBI-MB (NCT02039947) aims to assess the efficacy of dabrafenib combined with trametinib in the treatment of patients with BRAF mutation-positive melanoma which has metastasized to the brain. Meanwhile, the CheckMate204 trial examined the effectiveness of nivolumab in combination with ipilimumab, followed by single treatment with nivolumab. Prof. Ascierto explains the results and tells us why further clinical trials are important to improve therapy for these patients.
Get great new content delivered to your inboxSign up